Contribution: Industrial Research Assistance Program – Contributions to Firms
Pacylex Pharmaceuticals Inc
$158,000.00
Pre-clinical Development of a Novel Personalized Treatment for B Cell Lymphomas
FY 2016-17 · 2017-01-01
Summary
Pacylex has discovered a biomarker that is lower in certain cancers than normal tissue and that confers sensitivity to our drug. With extensive proof-of-efficacies on our precision medicine strategy in vitro and in vivo in hand, this project enables the next steps of animal safety testing of our lead drug PCLX-001 and further mechanism of action studies to enable an investigative new drug (IND) Health Canada filing so we can eventually start Phase I trials, ideally in Edmonton, AB, Canada.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Edmonton|Edmonton, Alberta, Canada
Recipient Type
For-profit organization
Business Number
825695588
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Additional Information
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 92 days.
Additional Information (French)
Cet accord a été modifié 2 fois La date de fin du présent accord a été changé de 92 jours.
Agreement End Date
2018-12-31
Agreement Number
878946
Agreement Start Date
2017-01-01
Agreement Title
Pre-clinical Development of a Novel Personalized Treatment for B Cell Lymphomas
Agreement Title (French)
Développement préclinique d'un nouveau traitement personnalisé pour les lymphomes à cellule B
Agreement Type
Contribution
Agreement Value
$158,000.00
Amendment Date
2018-08-17
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Pacylex has discovered a biomarker that is lower in certain cancers than normal tissue and that confers sensitivity to our drug. With extensive proof-of-efficacies on our precision medicine strategy in vitro and in vivo in hand, this project enables the next steps of animal safety testing of our lead drug PCLX-001 and further mechanism of action studies to enable an investigative new drug (IND) Health Canada filing so we can eventually start Phase I trials, ideally in Edmonton, AB, Canada.
Description (French)
Pacylex a découvert un biomarqueur plus faible dans certains cancers que les tissus normaux et qui confère une sensibilité à notre médicament. Grâce à la preuve d'efficacité de notre stratégie de médecine de précision in vitro et in vivo, ce projet permet aux prochaines étapes d'essais de sécurité des animaux de notre médicament PCLX-001 et à d'autres études de mécanisme d'action permettant d'enquêter sur un nouveau médicament (IND) présenté à Santé Canada afin que nous puissions éventuellement commencer les essais de phase I, idéalement à Edmonton, en Alberta, au Canada.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Manning
Federal Riding (French)
Edmonton Manning
Federal Riding Number
48016
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
825695588
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Pacylex Pharmaceuticals Inc
Recipient Postal Code
T5Y 3K7
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2018-2019-Q2-878946
